Objective: To evaluate the performance of 2 automated systems, Morpheus and Somnolyzer24X7, with various levels of human review/editing, in scoring polysomnographic (PSG) recordings from a clinical trial using zolpidem in a model of transient insomnia. Methods: 164 all-night PSG recordings from 82 subjects collected during 2 nights of sleep, one under placebo and one under zolpidem (10 mg) treatment were used. For each recording, 6 different methods were used to provide sleep stage scores based on Rechtschaffen & Kales criteria: 1) full manual scoring, 2) automated scoring by Morpheus 3) automated scoring by Somnolyzer24X7, 4) automated scoring by Morpheus with full manual review, 5) automated scoring by Morpheus with partial manual review, 6) automated scoring by Somnolyzer24X7 with partial manual review. Ten traditional clinical efficacy measures of sleep initiation, maintenance, and architecture were calculated. Results: Pair-wise epoch-by-epoch agreements between fully automated and manual scores were in the range of intersite manual scoring agreements reported in the literature (70%-72%). Pair-wise epoch-by-epoch agreements between automated scores manually reviewed were higher (73%-76%). The direction and statistical significance of treatment effect sizes using traditional efficacy endpoints were essentially the same whichever method was used. As the degree of manual review increased, the magnitude of the effect size approached those estimated with fully manual scoring. Conclusion: Automated or semi-automated sleep PSG scoring offers valuable alternatives to costly, time consuming, and intrasite and intersite variable manual scoring, especially in large multicenter clinical trials. Reduction in scoring variability may also reduce the sample size of a clinical trial.
INTRODUCTION

MANUAL SCORING OF PSG RECORDINGS AS ORIGINAL-LY DEFINED BY RECHTSCHAFFEN AND KALES
1 AND IN-SOMNIA DRUG EFFICACY ENDPOINTS DERIVED FROM this scoring are the "gold standard" for PSG data processing in sleep clinical trials and regulatory submissions in the pharmaceutical industry. Manual scorers rely on visual extraction of both dominant and transient signals within each recorded physiologic signal, and quantification of the preponderance of these signals within each 30-second interval or epoch. This is time consuming (typically 1-2 hours per patient night of PSG recording), costly (typically hundreds of dollars per single recording, or millions of dollars for a typical Phase III clinical trial) and prone to intersite scoring variability (due to differences in training and local classification customs).
The annual cost of sleep PSG scoring over all clinical trials is rapidly increasing due to the fact that more and more new drugs enter clinical trials. According to the Research and Market organization 2 "the global market for sleep-wake disorders was worth an estimated US$4.3 billion in 2005 and is forecast to increase 158% to US$11 billion by 2012." In spite of the high cost and lengthy time required for manual scoring, the between-scorer agreement may be problematic, particularly for scorers from different sites. For example, epoch-by-epoch intersite agreement between manual scorers in the United States 3, 4 ranges from 71% to 76%, consistent with reported European intersite agreement 5 of 76.8%. These agreements are substantially lower than agreements between scores at the same site 6, 7 and "warrant caution when comparing data scored in separate laboratories." 3 High variability of scoring leads to an arguably larger increase in the sample size of a clinical trial in order to obtain an appropriate statistical power, hence increasing the cost and lengthening the duration of the trial.
It is widely believed that implementation of computer algorithms designed for automatic R&K scoring of sleep EEG signals may significantly reduce scoring cost, time, and variability. Numerous scoring algorithms have been developed [8] [9] [10] and some of them are already used by sleep service providers. Promising results have been published 6, 11, 12 on the evaluation of 2 of these systems also considered in the present paper.
Previous evaluations were expanded here in a number of directions. First, automated and semi-automated systems for R&K scoring were considered specifically for application in evaluating traditional efficacy measures in a clinical trial of an insomnia treatment drug. Second, in order to avoid failures of automated scoring caused by, for example, EEG recording quality or the complexity of sleep architecture, some degree of human supervision is necessary; how the level of human supervision affects scoring quality was also investigated here. Finally, 2 automated scoring systems with different levels of human supervision performed at different sites were analyzed to determine both the agreements between scorings and differences in the treatment effect sizes of traditional efficacy endpoints used in clinical trials. † In the selection of automated scoring systems studied here, preference was given to systems that have been used by scoring service providers, whose performance had been previously evaluated on at least some clinical data, and whose algorithms and mathematical underpinnings have been published. Based on these criteria, two systems, Morpheus by WideMed, Ltd. (Israel) 6, 13 and Somnolyzer24X7 by The Siesta Group, Schlafanalyse GmbH (Vienna, Austria) 11 were selected.
METHODS
Subjects and Data
Eighty-two healthy subjects, (45 females, 37 males), mean age 31.8 (SD 10.0, range 18.7 -57.5) years, representing the per protocol set participated in a randomized, double-blind, placebo controlled, cross-over study of transient insomnia in which zolpidem 10 mg was used. All-night PSG recordings occurred in 1 of 6 clinical sleep centers in the United States; transient insomnia was induced by a 4-hour advancement of each subject's habitual bedtime. Treatments were administered orally 30 minutes before the advanced bedtime. For additional details of this study see Walsh et al. 14 In the present paper, 164 PSG recordings from 82 subjects collected during 2 nights of sleep, one under placebo and one under zolpidem 10 mg for each subject were used. The reason for selecting zolpidem 10 mg was its proven efficacy in a clinical trial 15 of transient insomnia, demonstrated using polysomnography and manual R&K scoring.
Procedures
Manual Scoring. Manual scoring was performed on 164 PSG recordings according to the R&K criteria at a central scoring lab in New York, NY by registered polysomnographic technologists (RPSGTs).
Morpheus Automated Scoring (A Auto ). The PSG recordings in EDF format 16 were transferred to SleepMed Inc., Columbia, SC. Recordings were re-referenced if necessary and scored automatically by Morpheus automated scoring software.
Morpheus Automated Scoring with Full Manual Review (A Full ). A registered polysomnographic technologist at SleepMed Inc, reviewed each 30-second epoch and changed the sleep stage classification of the epochs deemed to be incorrectly classified by automated scoring. Since each epoch of the recording receives manual review, the obtained scores represent another "replicate" of the manual scores obtained at a different site. For all but 2 recordings, the proportion of epochs requiring scoring changes ranged from 4.7% to 53.3% with a mean value of 22.2%. In the 2 recordings that were problematic for automated scoring due to high level of noise, the proportions were 84.7% and 90.4%. Both these recording were from the same subject.
Morpheus Automated Scoring with Partial Manual Review (A Partial ). For the study presented in this paper, automated scores from A Auto (above) were also submitted to partial review at WideMed Inc., Israel. A scorer with 15 years of scoring experience reviewed only epochs with automated scores of Wake or Stage 1 (stages deemed most likely to be miscoded by the automated algorithm). Automated scores from these epochs as well as neighboring epochs on either side of the epoch in question were altered as deemed necessary by the human scorer. Except for the 2 recordings which were problematic for automated scoring, the proportion of edited epochs ranged from 0.9% to 33.3% with a mean value of 10.2%. In the problematic recordings the proportions were 85.9% and 92.4%.
Somnolyzer24X7 Automated Scoring (B Auto ). PSG recordings were transferred to The Siesta Group, GmbH, Austria, where they were re-referenced if necessary and scored automatically using Somnolyzer24X7 automated scoring software. Three recordings were problematic for automated scoring because of nonstandard electrode placements (i.e., not according to R&K) and were scored manually. These 3 recordings were taken from 3 different subjects and were not the same recordings found to be problematic for Morpheus.
Somnolyzer24X7 Automated Scoring with Partial Manual Review (B Partial ). Selective quality control procedure 11 at The Siesta Group was done by 2 scorers certified according to the national Austrian standards (equivalent to RPSGT in the United States). In this procedure a scorer evaluates automated scores from B Auto (above) as well as intermediate results at various steps of the automated scoring procedure and, if necessary, the raw data. The scorer changes any automated scores deemed to be incorrect. Only 29% of recordings required human editing, including the 3 problematic recordings, which required full manual scoring. The proportion of epoch scores changed by the expert ranged from 0.4% to 21.0% with a mean value of 5.8%. Across all 161 recordings subjected to B Partial the mean number of corrected epochs was 1.6%.
All sites performing automated and semi-automated scoring were blinded to prior manual scoring, treatment conditions and scoring from other sites. Scorers were not aware that they were participating in a comparative study.
Data Analysis
Epoch-by-epoch pair-wise agreements between all pairs of scoring methods over all wake/sleep stages were calculated as the proportions of the number of epochs in which both methods agreed on the scoring among all epochs in the recording. Cohen's kappa 17 was calculated as an estimate of the agreements between methods corrected for their agreement at random. Sleep/wake stage specific agreements were calculated to compare manual scoring with all other methods. For all scoring strategies, traditional PSG variables were calculated and compared.
‡ The variables included total sleep time (TST; time spent in NREM and REM sleep plus the duration of body movement, MVT), latency to persistent sleep (LPS; lights out to the beginning of 10 consecutive minutes of uninterrupted sleep), wake after sleep onset (WASO; the total amount of time spent awake after onset of persistent sleep until lights on), number of awakenings (NAW; the number of wake epochs after sleep onset separated by any of the sleep intervals of at least one epoch duration), time spent in REM sleep (REM), REM sleep latency (RSL; time from sleep onset to the first epoch of REM), and time spent in 4 NREM sleep stages (ST1, ST2, ST3, and ST4). Paired t-tests were used to test statistical significance of pair-wise differences between mean treatment effect sizes. To change the distributions of the endpoints towards a normal distribution, values of the endpoints LPS, WASO, NAW, RSL, and ST1 were increased by 1.0 and then log transformed. 17 estimated agreement between 2 methods corrected for their agreement at random. Agreements between manual scoring and fully automated scoring were 70% for A Auto and 75.9% for A Partial (kappa was 54.8% and 62.7% respectively). Semi-automated scoring agreements with manual scoring ranged from 73.0% (B Partial ) to 75.9% (A Partial ) with kappa from 60.2% to 62.7%. Pair-wise Cohen's kappas between 41% and 60% are considered as "moderate" agreement while values between 61% and 80% are considered as "substantial" agreement. 18 By this measure agreements between manual scoring and A Auto , B Auto , and B Partial were "moderate" while A Partial and A Full were in "substantial" agreement with manual scoring. Similar ranges of manual scoring agreement between expert scorers at different sites have been reported by other authors. 3, 5 Partial manual review and editing of Morpheus automated scores substantially increased their agreement with manual scores, from 70% when fully automated to 75.6% with partial review. This increase was relatively small for Somnolyzer24X7, from 72.3% to 73.0%. Improvements due to partial review and editing are consistent with the percentage of epochs requiring scoring changes for each system, 10.2% for Morpheus and 1.6% for Somnolyzer24X7. Correcting sleep scoring in more epochs (e.g., 22.2% of epochs modified by full manual review, A Full ) resulted in 75.0% agreement with manual scoring, which is slightly less than that of partial review. This is because A Partial scoring had the highest agreement with manual scoring in ST2 (see below) while ST2 had the largest proportion of epochs among all stages, (46.3% and 58.6% on average for placebo and zolpidem, respectively).
RESULTS
Epoch-by-Epoch Agreement Analysis
The high agreement between A Full and A Partial , 82.8% (kappa, 74.2%), is of significant practical interest because both strategies for automated scoring correction were implemented independently at 2 different sites by different procedures. In spite of this, the overall agreement was as high as intrasite manual scoring reproducibility reported in the literature. 6 High agreement between scores achieved via manual review of different automatic systems and edited at different sites was also seen in the higher agreement between A Partial and B Partial , 77.7% (kappa, 66.9%) vs. A Partial and manual scoring, 75.9% (kappa, 62.7%) or B Partial vs. manual scoring, 73% (kappa, 60.2%). Tables 2a through 2e show the average (over all recordings) of epoch-by-epoch agreements for each pair of scorings. Sleep stage specific agreement with manual scoring was evaluated using 5 contingency tables, one for each automated and semi-automated scoring method. For each contingency table, rows were assigned to full manual scoring and columns assigned to the automated or semi-automated scoring. Table entries were row-normalized, i.e., divided by the row sums, and averaged over all records. For example, the first row of Table 2a shows that A Full scores as Wake the 76.5% of epochs scored by manual scoring as Wake. Also, 6.7% of the epochs scored as Wake by manual scoring were scored by A Full as ST1; 10.4% as ST2; 0.6% as ST3, 0.5% as ST4, 5.4% as REM, and 0.0% as MVT. Analysis of the data in Table 2 reveals some general trends. Both automated scorings, A Auto and B Auto , underscored the manually determined Wake stage, 58.4% for A Auto and 59.6% for B Auto . Partial review increased this agreement to 68.1% (A Partial ) and to 60.8% (B Partial ). A more significant increase for A Auto than for B Auto is because the Morpheus procedure for manual review specifically targets Wake stages while the Somnolyzer24X7 review is apparently less focused on this stage. Full manual review increased this agreement even more, to 76.5% (A Full ). Even this level of agreement in the Wake stage was lower than the intersite agreement between human scorings reported in the literature, 3, 6 81.0% to 82.0%. Remediation of this issue in automated and semi-automated scoring systems is an important step in their improvement.
Agreement with manual scoring in Stage 1 was significantly lower than in the other stages for all methods. Low agreement in ST1, 21.3%, was reported previously. 6 Partial manual review slightly improved agreement in ST1, for the Somnolyzer24X7 from 28.9% (B Auto ) to 30.6% (B Partial ). However, with Morpheus, partial manual review reduced the agreement from 26.3% (A Auto ) to 16.6% (A Partial ). This is quite surprising since the Morpheus partial review procedure specifically targets ST1. Note that the A Full scoring yielded ST1 agreement equal to 28.7%, which is just slightly better than A Auto agreement of 26.3%. Agreements with manual scoring in Stages 3, 4, and REM for B Auto , B Partial , A Partial , and A Full were similar or even higher than those reported in the literature for intersite and even intrasite agreements between manual scorers. 3, 5, 6 A Auto scoring gave a somewhat lower agreement in the REM stage, 68%, which increased to 87.1% and to 83.4% after partial or full reviewing, respectively. Agreement with manual scoring with respect to MVT was very high for all methods. 
Treatment Effect and Endpoint Analysis
Tables 3a through 3k contain means or geometric means of the sleep efficacy and architecture endpoints, their treatment effect sizes, and their 95% upper and lower confidence limits. To facilitate method comparison, Figure 2 specifically shows the treatment effects and their statistical significance.
According to manual scoring, zolpidem had a clear statistically significant increase in TST (P <0.001), as well as in stages ST2 (P< 0.001), ST3 (0.001≤ P<0.01), and ST4 (P <0.001). There was also a clear statistically significant decrease in LPS (P <0.001) and WASO (P <0.001). The decrease in NAW, characterized by the ratio of treatment and placebo geometric means being 0.92, was on the "border" of significance, since the upper confidence limit rounded to the second decimal place is equal to 1. The trends in REM, RSL, and ST1 were not statistically significant and hence have an uncertain interpretation with the data in hand. The effect of zolpidem on the increase in TST and decrease in LPS and NAW has been observed previously in a transient insomnia clinical trial. 15 Some statistically significant effects observed in our study such as the decrease in WASO and a large increase in time spent in ST2 are very much related to the corresponding changes in TST and LPS. The other, relatively small but statistically significant increases in ST3, ST4 could be specific for the study discussed in our paper. Table 4 shows results from the testing of whether the effect size calculated by one scoring method is different from that calculated by another method. Results are given for all endpoints and selected pair-wise comparisons discussed further.
If automated scoring with full manual review, A Full , was used, then all the above findings on the treatment effects calculated by manual scoring were substantially unchanged in direction, in magnitude, or in significance. The exception was NAW, which was different in significance but not in magnitude, and ST2, ST4 which were different only in magnitude. The disagreement in the significance of the NAW effect is of a nature commonly occurring when P-values are very close to the chosen significance level, 0.05 in our case. The magnitude of the effect in ST2 was lower by 14.5, minutes while in ST4 it was higher by 9.3 minutes. Given that these scores have a full manual review, it is not certain whether they were more accurate or less accurate than a fully manual procedure.
If automated scoring with partial manual review, A Partial , was used, the findings on the treatment effects revealed by manual scoring were substantially unchanged in direction and in significance. An exception is the effect on ST1, 0.83 vs. 0.92 for manual, which was different in significance but not in magnitude. In terms of magnitude of the effects, the hypothesis of no difference with manual scoring cannot be rejected for TST, LPS, REM, ST1, and ST3 and was rejected for RSL, WASO, NAW, ST2, ST4. Differences in RSL between methods were not surprising since this endpoint usually has high variance because of the difficulty of establishing the very first occurrence of REM. The underestimation of WASO and NAW by A Partial compared to the manual scoring was because of a relatively low agreement of these 2 methods in the WAKE stage discussed earlier. The underestimation of the effect on ST2 by 13.6 minutes and the overestimation of the effect on ST4 by 6.4 minutes were similar to that for A Full scoring.
If automated scoring with partial manual review, B Partial , was used, the findings on the treatment effects revealed by manual scoring were substantially unchanged in direction and significance. Exceptions were the effect on ST1, which was different in significance but not in magnitude, and effects on REM, -6.6 minutes (P < 0.05) versus -2.3 minutes (NS) which were different in both significance and magnitude. In terms of the magnitude of the effects and in addition to ST1, the hypothesis of no difference with manual scoring could not be rejected for LPS and RSL, while it was rejected for the others. Differences in TST although statistically significant, were relatively small, i.e., less than 10% of the effect estimated by the manual scoring. Differences in WASO and NAW were most likely due to a somewhat low agreement between B Partial and manual scoring for the WAKE stage. The fact that B Partial also underestimated the effect on ST2 (14.6 minutes) and overestimated the effect on ST4 (5.4 minutes) supports the view that it is the manual scoring that may not accurately estimate effects on ST2 and ST4.
The findings on the treatments effects by A Auto and B Auto were basically the same in direction and in significance as the findings of their partially manually reviewed versions, A Partial and B Partial , described above. An exception was the effect on stage ST1 where the effect by A Auto was 1.17 (P <0.05) which was "corrected" by A Partial to a value 0.83 (P <0.05) much closer to the effect calculated by manual scoring. Another exception was WASO where the effect by B Auto was 0.45 (P <0.001) while the effect by B Partial was 0.41 (P <0.001) which is slightly less close to the effect calculated by manual scoring. In general, manual reviewing of the A Auto scores resulted in more accurate estimates of the treatment effect sizes in the sense that these estimates were closer to the ones calculated by manual scoring. Manual review of the B Auto scores had only a small impact on either increase or decrease in accuracy.
It is important to point to a somewhat complex relation between stage-specific agreements of any 2 scoring methods and the differences in the corresponding endpoint and effect size estimates. For example, there was a relatively high (86%) agreement between A Full and manual scoring in Stage 4 (Table 2a) , but the corresponding effect sizes had a statistically significant difference of 9.3 minutes (Table 4 ). This underscores a limitation of evaluation of sleep scoring methods exclusively on the analysis of their epoch-by-epoch agreements. (The relation between the agreements and corresponding endpoints can be found via a mathematical analysis which is beyond the scope of this paper.)
DISCUSSION
Automated R&K scoring of sleep PSG recordings in clinical trials is rapidly becoming a necessity rather than an option, due to the dramatic increase in the number of PSG recordings which have to be scored. Continuing the practice of manual scoring is prohibitively expensive and time consuming. Moreover, as has been demonstrated in the literature, the reproducibility of manual scoring for some of the sleep stages, and especially between different scoring sites, is relatively low. In spite of a number of reports in the literature illustrating a reasonably high performance of automated scoring procedures, there is still reluctance in the sleep research community to adopt a much wider application of automated scoring. One of the reasons for this reluctance is a concern that, without any human intervention, the automated systems may not be capable of providing high accuracy R&K scoring for data of varying quality and/or sleep fragmentation. This concern is based on experience showing that the accuracy of offthe-shelf automated scoring software, with the default parameters established by their vendors, is not comparable to the accuracy of manual R&K scoring. It is unlikely also that even the most advanced computer algorithms of the type considered in this paper will completely match how a human expert applies the R&K rules. There will always be some recordings where, whether due to poor quality and/or particularly difficult sleep architecture, a *, **, and *** correspond to P < 0.05, 0.001 ≤ P < 0.01, and P < 0.001, respectively. NS means that the hypothesis of no treatment effect cannot be Mean effect sizes for LPS. WASO, NAW, RSL, and ST1 are ratios of the geometric means of the corresponding endpoints. *, **, *** correspond to P < 0.05, 0.001 ≤ P < 0.01, P < 0.001 respectively. NS means that the hypothesis of no treatment effect cannot be rejected.
human expert will be able to see the features defined by R&K rules better than a computer algorithm does. The fundamental paradox is that computer algorithms that are capable of correctly extracting very informative sleep EEG features sometimes fail to convert them into not as informative but well established R&K sleep stages defined specifically for human scoring. A comprehensive discussion of this issue can be found in Himanen et al. 19 Concerns related to the possible failures of strictly automated scoring can be addressed by combining it with manual review and editing of the automated scores by an experienced PSG scorer. In this paper a comprehensive analysis of possible options for this combination based on two different automated scoring systems with varying levels of human involvement was presented. Putting them in ascending progression of the level of human involvement and increasing accuracy of scoring, one can start by considering a purely automated scoring with only a few recordings (2 for Morpheus and 3 for Somnolyzer24X7 in our data), which for reasons of either poor quality or data format incompatibility were scored manually, while the others were scored without any post-processing review. This type of scoring will provide the maximum savings in time and cost compared with manual scoring. The epoch-by-epoch agreement between automated and manual scores, however, was relatively low, 70% (kappa, 54.8%) for Morpheus and 72.3% (kappa, 59.1%) for Somnolyzer24X7. The findings on significance and the directions of the mean treatment effect sizes based on these scores were the same as that of manual scoring for major clinical sleep initiation and maintenance efficacy endpoints, TST, LPS, WASO, NAW, as well as sleep architecture measures of REM (Morpheus only), RSL (Somnolyzer24X7 only), ST2, ST3, and ST4. The magnitude of the effects are statistically different for 6 out of 10 endpoints for both methods.
The next 2 levels of human involvement included a very limited manual reviewing and editing by Somnolyzer24X7, (on average 1.6% of the epochs were changed in our data) and more intensive editing by Morpheus (10.2% in our data). The less intensive manual reviewing by Somnolyzer24X7 did not have a substantial impact on the accuracy of scoring. The epoch-byepoch agreement with the manual scoring was changed by only 0.7% to 73.0% while kappa was changed by 1.1% to 60.2%. The findings on the treatment effect sizes were mostly the same as that of the automated scoring.
The more intensive manual reviewing by Morpheus was more beneficial for accuracy. It raised the epoch-by-epoch agreement with manual scoring to 75.9% (kappa, 62.7), and added ST1 to 
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-
9.3 min 6.4 min 6.2 min 5.5 min 5.5 min ns ns ns 11.5
One, two, or three pluses (minuses) correspond to P < 0.05, 0.001≤ P< 0.01, and P< 0.001 with plus (minus) indicating that the effect size calculated by the method written as the first in the column heading is higher (lower) than the second one. ns means that the hypothesis of no difference between effect sizes cannot be rejected. Values in the first column are means or geometric means of the effect sizes calculated using manual scoring. Values in other columns are the differences in the mean effect sizes calculated using different scorings, and are shown for only those cases when these differences are statistically significant.
Automated Sleep Scoring Evaluation-Svetnik et al the list of treatment effects whose direction, significance, and magnitude were similar to that of manual scoring.
The full manual review and editing of the Morpheus scores represent the highest level of manual involvement and provides the closest proximity to manual scoring in terms of endpoint estimates and treatment effect sizes. Specifically, the findings on significance, direction, and magnitudes of treatment effect size were substantially the same as that of manual scoring for all endpoints except for ST2 and ST4. In general, since Morpheus scoring with full manual review for all intents and purposes is equivalent to manual scoring alone, the observed differences between them should be considered as intersite manual scorer-to-scorer variability.
The cost of some commercially available semi-automated scoring services depends on the level of manual review and could be 3 to 5 times less than the cost of human scoring in the case of partial review; it is about the same as the cost of manual scoring if a full review is used. 3 Even if the cost is not reduced, as would be the case for a full manual review, there is a significant practical interest in achieving a substantially higher intersite reproducibility of the semi-automated scoring compared with manual scoring. This reproducibility is evident from a high epoch-by-epoch agreement of 82.8% (kappa, 72.4%) between scorers performing full or partial review of Morpheus scores. This agreement is only 75% (kappa, 62.4), and 75.6% (kappa, 62.7) between manual scoring and automated scorings with full or partial review, respectively. Also, treatment effects based on these two groups of scores are closer to each other than to those based on manual scores. This trend of a higher agreement between scores derived even by different automatic systems and edited at different sites, is also seen in the higher agreement between Morpheus and Somnolyzer24X7 (A Partial and B Partial ), 77.7% (kappa, 66.9%) vs. A Partial and manual scoring, 75.9% (kappa, 62.7%) or B Partial and manual scoring, 73% (kappa, 60.2%). The treatment effect estimates for these 2 methods are also closer to each other than to those of manual scoring. Reduction in scoring variability may also lead to a reduction in the sample size of a clinical trial while preserving the required statistical power hence reducing the cost and duration of the trial.
Current practice for processing data from a large clinical trial is to use one centralized scoring site for human scoring of all PSG data. Operating procedures implemented at this site ensure a high within-site scorer-to-scorer reproducibility. Examples of these procedures include re-scoring of a substantial fraction of recordings and assigning one scorer to score all recordings from one subject/patient. On the other hand, steps to improve between-site reproducibility of manual scoring are very limited. Results in this paper suggest a possible direction for the industry-wide improvement of the intersite scoring reproducibility. This can be done with simultaneous reduction in the scoring cost and time while maintaining high within-site reproducibility. The steps in this direction include a transition from a completely manual scoring to the use of industry accepted automated systems. These systems implemented at the centralized sites will generate baseline automated scores which then, if necessary, will be manually reviewed and edited according to common procedures with some data-specific or site-specific modifications. Increase in the intersite reproducibility will have a clear clinical implication by enhancing the interpretation of published data collected at different sites and by facilitating meta-analysis of clinical trial data.
For automated and semi-automated PSG scoring to become widely used, a number of issues have to be addressed. First, the cost of partially reviewed and edited automated scoring should be kept significantly lower than that of manual scoring in order to become an attractive option for the scoring of PSG data in large clinical trials. Second, protocols for partial review have to be optimized to provide a high agreement with manual scoring at a reduced cost. For example, both procedures considered in this paper should be modified to obtain a better agreement with manual scoring in the Wake stage and hence improve the proximity of WASO and NAW treatment effect sizes to those of manual scoring. In general, manual reviewing procedures may reflect specifics of the data such as, for example, data quality, patient population, and degree of sleep fragmentation. Third, more studies should be done to further investigate improvements in the intersite scoring reproducibility due to the use of manually reviewed automated scorings.
FOOTNOTES † After this manuscript was submitted, a comprehensive review 20 was published surveying 45 citations related to computerized scoring of PSG recordings. According to the grading system in this review, the present paper would receive the highest grade as a performance evaluation study in terms of the sample size, representativeness of the sample, and type of analyses.
‡ Some small differences between endpoints calculated from manual scores in this paper and the endpoints in Walsh, et al14 can be attributed to the differences in the endpoint definitions and their calculations by different software.
